Why the study?
Mutations in KV7.1/KCNE1 causing channel loss-of-function frequently lead to congenital long QT syndrome. The study examined whether the endocannabinoid ARA-S can facilitate activation of LQTS-associated mutated channels across various channel regions and counteract loss-of-function.
Population
Xenopus oocytes expressing human KV7.1/KCNE1 with 20 LQTS type 1-associated mutations, mammalian cells, and cardiomyocytes
Comparison
Effects of ARA-S across mutated channels
Design
Preclinical in vitro electrophysiology study
Key result
ARA-S enhanced the function of 20 LQTS type 1-associated mutated channels by shifting V50 and increasing current amplitude, and shortened the action potential duration in cardiomyocytes.
Authors
Loading...
Supports targeted LQTS type 1 therapy development; leaves open translation from animal models to patients.
ARA-S rescues loss-of-function in diverse LQTS type 1-associated KV7.1/KCNE1 mutations, highlighting its potential for developing targeted therapies for long QT syndrome.
Hiniesto‐Iñigo et al. (2025) studied Congenital long QT syndrome (LQTS). N-arachidonoyl-L-serine (ARA-S) was evaluated on Channel function (V50 and current amplitude). ARA-S enhanced the function of 20 LQTS type 1-associated mutated channels by shifting V50 and increasing current amplitude, and shortened the action potential duration in cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: